Proton Pump Inhibitors in Renal Disease and Ace-1/ARBS Considered & Nature vs Nurture: Integrative Strategies to Treat Obesity-2018 WOMA Primary Care Update is organized by DO CME.
Credit: 2 AOA Category 1-A Credit (WOMA)
Original Program Date: June 7, 2018
Access: Available for 3 months after purchase
Proton Pump Inhibitors in Renal Disease and Ace-1/ARBS Considered:
Proton Pump Inhibitors (PPIs) and ACE-I/ARBs have become some of the most widely prescribed medications in the past several decades. A number of recent studies have implicated PPIs in a variety of acute and chronic renal conditions and other associated medical conditions. Should ACE-I/ARBs be discontinued in the face of advanced CKD? New research is suggesting this, but what is the cost to benefit? This talk sorts through the data to give a clear recommendation for these medications.
Nature vs Nurture: Integrative Strategies to Treat Obesity:
The etiology of obesity is complex. Individual variation in BMI is influenced by genomics, but genomics does not explain the surge in obesity rates over the past 30 years. Epigenetic imprinting during critical stages of development substantially impacts the heritability of obesity. Unlike genomics, which is unmodifiable, interventions targeting epigenetic imprinting show promise in obesity prevention. Beyond the imprinting stage of obesity prevention, treatment recommendations for obesity and weight maintenance are reviewed, with emphasis on integrative cognitive and lifestyle approaches.
Additional details will be posted as soon as they are available.
Endocrinology, Gastroenterology, Primary Care, Nephrology
Activity Payment Details
Reviews Given by Professionals
Browse by Specialty (Online CME/CE Only) View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Immunology and Microbiology
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine